A Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Adult Subjects With Relapsed or Refractory T or B Cell Malignancies
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
CRISPR Therapeutics
Start Date
March 1, 2022
End Date
June 30, 2027
Administered By
Duke Cancer Institute
Awarded By
CRISPR Therapeutics
Start Date
March 1, 2022
End Date
June 30, 2027